1 Year Absolute Returns
-
NAV (₹) on 08 May 2026
19.81
1 Day NAV Change
0.28%
Risk Level
Very High Risk
Rating
-
Mirae Asset Nifty 500 Healthcare ETF is a Equity mutual fund categorized under ETF, offered by Mirae Asset Global Investments (India) Pvt. Ltd.. Launched on 27 Jan 2026, investors can start with a ... Read more
AUM
₹ 7.62 Cr
| Sectors | Weightage |
|---|---|
| Pharmaceuticals | 76.07% |
| Hospitals & Medical Services | 23.07% |
| Medical Equipment & Accessories | 0.40% |
| Services - Others | 0.40% |
| Treps/Reverse Repo | 0.17% |
| Name | Weightage | Value (in Cr.) | Sector |
|---|---|---|---|
| Sun Pharmaceutical Industries Ltd. | 10.03% | ₹ 0.76 | Pharmaceuticals |
| Dr. Reddy's Laboratories Ltd. | 6.75% | ₹ 0.51 | Pharmaceuticals |
| Apollo Hospitals Enterprise Ltd. | 6.75% | ₹ 0.51 | Hospitals & Medical Services |
| Divi's Laboratories Ltd. | 6.67% | ₹ 0.51 | Pharmaceuticals |
| Max Healthcare Institute Ltd. | 6.32% | ₹ 0.48 | Hospitals & Medical Services |
| Cipla Ltd. | 6.08% | ₹ 0.46 | Pharmaceuticals |
| Lupin Ltd. | 4.95% | ₹ 0.38 | Pharmaceuticals |
| Torrent Pharmaceuticals Ltd. | 3.90% | ₹ 0.30 | Pharmaceuticals |
| Fortis Healthcare Ltd. | 3.66% | ₹ 0.28 | Hospitals & Medical Services |
| Laurus Labs Ltd. | 3.41% | ₹ 0.26 | Pharmaceuticals |
| Aurobindo Pharma Ltd. | 3.22% | ₹ 0.25 | Pharmaceuticals |
| Glenmark Pharmaceuticals Ltd. | 2.83% | ₹ 0.22 | Pharmaceuticals |
| Alkem Laboratories Ltd. | 2.73% | ₹ 0.21 | Pharmaceuticals |
| Biocon Ltd. | 2.28% | ₹ 0.17 | Pharmaceuticals |
| Mankind Pharma Ltd. | 2.00% | ₹ 0.15 | Pharmaceuticals |
| IPCA Laboratories Ltd. | 1.96% | ₹ 0.15 | Pharmaceuticals |
| Zydus Lifesciences Ltd. | 1.92% | ₹ 0.15 | Pharmaceuticals |
| Aster DM Healthcare Ltd. | 1.50% | ₹ 0.11 | Hospitals & Medical Services |
| JB Chemicals & Pharmaceuticals Ltd. | 1.49% | ₹ 0.11 | Pharmaceuticals |
| Krishna Institute of Medical Sciences Ltd. | 1.36% | ₹ 0.10 | Hospitals & Medical Services |
| Gland Pharma Ltd. | 1.19% | ₹ 0.09 | Pharmaceuticals |
| Abbott India Ltd. | 1.19% | ₹ 0.09 | Pharmaceuticals |
| Sai Life Sciences Ltd. | 1.18% | ₹ 0.09 | Pharmaceuticals |
| Acutaas Chemicals Ltd. | 1.17% | ₹ 0.09 | Pharmaceuticals |
| Ajanta Pharma Ltd. | 1.05% | ₹ 0.08 | Pharmaceuticals |
| Narayana Hrudayalaya Ltd. | 0.98% | ₹ 0.07 | Hospitals & Medical Services |
| Neuland Laboratories Ltd. | 0.92% | ₹ 0.07 | Pharmaceuticals |
| Dr. Lal Path labs Ltd. | 0.90% | ₹ 0.07 | Hospitals & Medical Services |
| Wockhardt Ltd. | 0.86% | ₹ 0.07 | Pharmaceuticals |
| Glaxosmithkline Pharmaceuticals Ltd. | 0.83% | ₹ 0.06 | Pharmaceuticals |
| Granules India Ltd. | 0.80% | ₹ 0.06 | Pharmaceuticals |
| Natco Pharma Ltd. | 0.77% | ₹ 0.06 | Pharmaceuticals |
| Piramal Pharma Ltd. | 0.75% | ₹ 0.06 | Pharmaceuticals |
| Global Health Ltd. | 0.72% | ₹ 0.05 | Hospitals & Medical Services |
| Onesource Specialty Pharma Ltd. | 0.72% | ₹ 0.05 | Pharmaceuticals |
| Syngene International Ltd. | 0.65% | ₹ 0.05 | Pharmaceuticals |
| Pfizer Ltd. | 0.63% | ₹ 0.05 | Pharmaceuticals |
| Eris Lifesciences Ltd. | 0.63% | ₹ 0.05 | Pharmaceuticals |
| Jubilant Pharmova Ltd. | 0.58% | ₹ 0.04 | Pharmaceuticals |
| Rainbow Children's Medicare Ltd. | 0.51% | ₹ 0.04 | Hospitals & Medical Services |
| Emcure Pharmaceuticals Ltd. | 0.48% | ₹ 0.04 | Pharmaceuticals |
| Cohance Lifesciences Ltd. | 0.43% | ₹ 0.03 | Pharmaceuticals |
| Indegene Ltd. | 0.40% | ₹ 0.03 | Services - Others |
| Polymedicure Ltd. | 0.40% | ₹ 0.03 | Medical Equipment & Accessories |
| Vijaya Diagnostic Centre Ltd. | 0.37% | ₹ 0.03 | Hospitals & Medical Services |
| Anthem Biosciences Ltd. | 0.36% | ₹ 0.03 | Pharmaceuticals |
| Concord Biotech Ltd. | 0.30% | ₹ 0.02 | Pharmaceuticals |
| Caplin Point Laboratories Ltd. | 0.26% | ₹ 0.02 | Pharmaceuticals |
| TREPS | 0.17% | ₹ 0.01 | Others |
| Blue Jet Healthcare Ltd. | 0.10% | ₹ 0.01 | Pharmaceuticals |
| Annualised returns | ||||
|---|---|---|---|---|
| 9M | 1Y | 2Y | 3Y | |
| Fund returns | - | - | - | - |
| Category returns | 6.64% | 10.13% | 10.14% | 26.53% |
The investment objective of the scheme is to generate returns, before expenses, that are commensurate with the performance of the Nifty 500 Healthcare Total Return Index, subject to tracking error. ... Read more
|
Scheme Name
|
NAV
|
Returns
1Y
3Y
5Y
|
AUM (Cr)
|
Expense Ratio
|
Risk Meter
|
||
|---|---|---|---|---|---|---|---|
|
Taurus Nifty 50 Index Fund - Direct Plan
Index
Direct
|
₹45.74 | -0.11% | 32.80% | 64.26% | ₹6 | 0.92% |
Very High
|
|
Taurus Nifty 50 Index Fund - Direct Plan
Index
Direct
|
₹48.88 | -0.11% | 32.80% | 64.26% | ₹6 | 0.92% |
Very High
|
|
Nippon India Nifty 50 Value 20 Index Fund
Index
Regular
|
₹17.55 | -2.58% | 32.58% | 69.37% | ₹912 | 0.78% |
Very High
|
|
Nippon India Nifty 50 Value 20 Index Fund
Index
Regular
|
₹17.55 | -2.58% | 32.58% | 69.37% | ₹912 | 0.78% |
Very High
|
|
Nippon India Nifty 50 Value 20 Index Fund
Index
Regular
|
₹17.55 | -2.58% | 32.58% | 69.37% | ₹912 | 0.78% |
Very High
|
|
LIC MF Nifty 50 Index Fund
Index
Regular
|
₹49.11 | -0.36% | 32.41% | 63.58% | ₹335 | 1.08% |
Very High
|
|
LIC MF Nifty 50 Index Fund
Index
Regular
|
₹49.11 | -0.36% | 32.41% | 63.58% | ₹335 | 1.08% |
Very High
|
|
LIC MF Nifty 50 Index Fund
Index
Regular
|
₹133.12 | -0.36% | 32.41% | 63.58% | ₹335 | 1.08% |
Very High
|
|
Axis Nifty 100 Index Fund
Index
Regular
|
₹20.24 | -3.13% | 32.32% | 59.91% | ₹1,792 | 0.92% |
Very High
|
|
Axis Nifty 100 Index Fund
Index
Regular
|
₹20.24 | -3.13% | 32.32% | 59.91% | ₹1,792 | 0.92% |
Very High
|
What is the current NAV of Mirae Asset Nifty 500 Healthcare ETF Regular Growth?
What is the fund size (AUM) of Mirae Asset Nifty 500 Healthcare ETF Regular Growth?
What are the historical returns of Mirae Asset Nifty 500 Healthcare ETF Regular Growth?
What is the risk level of Mirae Asset Nifty 500 Healthcare ETF Regular Growth?
What is the minimum investment amount for Mirae Asset Nifty 500 Healthcare ETF Regular Growth?
Disclaimer: This is 3rd Party content/feed, viewers are requested to use their discretion and conduct proper diligence before investing, GoodReturns does not take any liability on the genuineness and correctness of the information in this article